A Phase 2 interventional study of Camrelizumab and Camrelizumab plus microwave ablation in NSCLC Stage IV, sponsored by Shandong Provincial Hospital. Status unknown at 13 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-02.
Sponsored by Shandong Provincial Hospital · Phase 2, Interventional, and Other
Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days.
The primary end point is overall survival. The second end points include progression free survival, objective response rate and safety.
Shandong Provincial Hospital is the lead sponsor of 58 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
Other: Camrelizumab plus microwave ablation
Patients in the group are treated with camrelizumab alone.
Drug: Camrelizumab
Patients will be treated with camrelizumab alone.
In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
Also known as: Camrelizumab plus MWA
Objective response rate
ORR
Time frame: The proportion of Patients achieved complete response or partial response up to 16 weeks
Overall survival
OS
Time frame: From date of randomization until the date of first documented date of death from any cause，assessed up to 24 months
Progression free survival
OS
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Safety
The adverse events of both microwave and camrelizumab
Time frame: The proportion and grade of patients had adverse events up to 24 months
Plan to share: No — Principle of confidentiality
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shandong Provincial Hospital